Ma Chong, Jin Ri-Ming, Chen Ke-Ji, Hao Tao, Li Bao-Song, Zhao Da-Hua, Jiang Hong
Department of Colorectal and General Surgery, Binzhou Medical University Hospital, Binzhou, 256603, China.
The First Department of Liver Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Pathol Res Pract. 2018 May;214(5):661-666. doi: 10.1016/j.prp.2018.03.023. Epub 2018 Mar 31.
Colorectal cancer (CRC) is one of the most common cancers worldwide. B cell-associated protein 31 (BAP31) was shown to participate in the apoptosis, and to be an immunotherapy target and a, prognostic factor for cancer, but its role in CRC has not been elucidated. In this study, we examined the expression of BAP31 in CRC to evaluate its prognostic values. We investigated the BAP31 expression level in 142 tissues (108 CRC and 17 paired human adjacent normal mucosa, and 17 liver metastatic CRC tissues) from 108 patients, using tissue microarray-based immunohistochemistry. We further investigated the association between BAP31 expression and overall survival (OS) and disease-free survival (DFS) in 77 CRC patients using Kaplan-Meier analysis. Univariate and multivariate Cox regression analyses were applied to evaluate the potential prognostic value of BAP31 in CRC patients. BAP31 expression level was significantly increased in CRC tissues (p = 0.0014) and liver metastatic CRC tissues (p < 0.0001) compared with corresponding adjacent normal mucosa. BAP31 expression was also significantly increased in liver metastatic CRC tissues compared with corresponding primary CRC tissues (p = 0.0116). Kaplan-Meier analyses showed that CRC patients with low BAP31 expression had significantly lower survival rate (p = 0.001) and lower disease-free survival rate (P = 0.009). Furthermore, multivariate Cox analysis showed that BAP31 was an independent prognostic factor for OS (hazard ratio = 0.410, 95% confidence interval = 0.195-0.862, p = 0.019).
Our study demonstrated that BAP31 is a potential prognostic marker for CRC patients after surgery.
结直肠癌（CRC）是全球最常见的癌症之一。B细胞相关蛋白31（BAP31）已被证明参与细胞凋亡，是一种免疫治疗靶点和癌症预后因素，但其在结直肠癌中的作用尚未阐明。在本研究中，我们检测了结直肠癌中BAP31的表达，以评估其预后价值。我们使用基于组织芯片的免疫组化方法，研究了108例患者的142个组织（108个结直肠癌组织、17对人相邻正常黏膜组织和17个肝转移结直肠癌组织）中BAP31的表达水平。我们使用Kaplan-Meier分析进一步研究了77例结直肠癌患者中BAP31表达与总生存期（OS）和无病生存期（DFS）之间的关联。采用单因素和多因素Cox回归分析评估BAP31在结直肠癌患者中的潜在预后价值。与相应的相邻正常黏膜相比，结直肠癌组织（p = 0.0014）和肝转移结直肠癌组织（p < 0.0001）中BAP31表达水平显著升高。与相应的原发性结直肠癌组织相比，肝转移结直肠癌组织中BAP31表达也显著升高（p = 0.0116）。Kaplan-Meier分析表明，BAP31表达低的结直肠癌患者生存率显著较低（p = 0.001），无病生存率也较低（P = 0.009）。此外，多因素Cox分析表明，BAP31是OS的独立预后因素（风险比 = 0.410，95%置信区间 = 0.195 - 0.862，p = 0.019）。
我们的研究表明，BAP31是结直肠癌患者术后的潜在预后标志物。
